Search
Botaretigene sparoparvovec
go.drugbank.com/drugs/DB16814InvestigationalSynonyms: ADENO-ASSOCIATED VIRUS 2 INVERTED TERMINAL REPEAT FL, DNA (RECOMBINANT PSEUDOTYPED ADENO-ASSOCIATED VIRUS 5 VECTOR AAV-RPGR HUMAN RHODOPSIN KINASE PROMOTER FRAGMENT-REGULATED HUMAN RETINITIS PIGMENTOSA GTPASE REGULATOR RPGR-ORF15 ISOFORM GENE VARIANT PLUSSelenious acid
go.drugbank.com/drugs/DB11127ApprovedSelenious acid is the acid form of sodium selenite, a form of selenium [L1910]. Selenium is an essential trace element and antioxidant. It is a cofactor metabolic enzyme regulation. … One study showed efficacy in the prevention of malignancy while utilizing a selenium supplement in humans.
Mixtures: TRACUTIL® 10 ML AMPOLLAS, Tricare Prenatal 2-part Daily Prenatal Vitamin SystemProducts: Selenase 100 Mikrogramm/2 ml - Lösung zum Einnehmen, Selepen Inj 40mcg/ml USPMaprotiline
go.drugbank.com/drugs/DB00934ApprovedMaprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: LUDIOMIL 25 MG TABLET, 30 ADET, MAPROTIL 25 MG TABLET, 30 ADETDeferasirox
go.drugbank.com/drugs/DB01609ApprovedInvestigationalDeferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP1A2 InhibitorsProducts: RASIROX® 500 MG, JEDOXRED® 360 MGHydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSynonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineBarth Syndrome
go.drugbank.com/conditions/DBCOND0000526Drugs: ElamipretideSynonyms: 3-Methylglutaconic aciduria type 2 (disorder)Eltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REVOLADE® TABLETAS 25 MG, REVOLADE ® TABLETAS 50 MGEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: XTANDI ® 40 MG, XTANDI® 40 MGRanolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.
Categories: MATE 2 Inhibitors, MATE 1 InhibitorsProducts: RANEXICOR ® 500, RANEXICOR ® 1000Stage 4 Pancreatic adenocarcinoma
go.drugbank.com/conditions/DBCOND0025282Drugs: GemcitabineSynonyms: Stage 4 Pancreatic adenocarcinoma